No Data
Earnings Preview: SGMO to Report Financial Results Post-market on May 12
Press Release: Sangamo Therapeutics Announces First Quarter 2025 Earnings Call
Sangamo Therapeutics Announces Derisking Milestones For Pathway To Anticipated BLA Submission For ST-920 In Fabry Disease
Express News | Sangamo Therapeutics: St-920 Study Pivotal Data Readout Expected by End of Q2 2025
Express News | Sangamo Therapeutics To Present At 28th Annual Meeting of the American Society of Gene & Cell Therapy May 13-17
TD Cowen Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating